Latest Commercialisation Strategies News

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.

Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.

Temas Resources has inked a Letter of Intent to validate its patented Regenerative Chloride Leach technology on a major refractory gold deposit, paving the way for a joint venture to commercialise the platform in Western North America.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

4DMedical has secured a commercial contract with University of Chicago Medicine to deploy its CT, VQ™ lung imaging technology, marking the fifth major US academic medical centre to adopt the platform since FDA clearance.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

xReality Group Limited has reported its strongest quarter yet, with record cash receipts and a doubling sales pipeline, underpinned by major US defence contracts and expanded production capacity.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.